Literature DB >> 17228487

Statin therapy in cardiovascular diseases other than atherosclerosis.

Dominique Beaudry, Kenneth E Stone, Suzanne Wetherold, John Hemphill, Dat Do, John McClish, Robert Chilton.   

Abstract

Statins are drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, thereby blocking the synthesis of cholesterol. Since being discovered in Japan in the mid 1970s, statins have been widely used to lower low-density lipoprotein cholesterol. However, analysis of cardiovascular research has revealed other important effects beyond changes in lipid parameters, referred to as pleiotropic effects. This paper focuses on the effects of statins as anti-ischemic agents with improvement in endothelial function, along with studies on valvular aortic stenosis, atrial fibrillation, heart failure, peripheral arterial disease, and cancer. As the evolution of statin research continues, there appear to be new potential benefits from statins to be found in many facets of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17228487     DOI: 10.1007/BF02693937

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  105 in total

1.  C-reactive protein and oxidative stress in atrial fibrillation.

Authors:  Panagiotis Korantzopoulos; Dimitrios Galaris; Dimitrios Papaioannides; Stelianos Kokkoris
Journal:  Int J Cardiol       Date:  2003-03       Impact factor: 4.164

2.  The risk of cancer in users of statins.

Authors:  Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

3.  Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein.

Authors:  David Amar; Hao Zhang; Paul M Heerdt; Bernard Park; Martin Fleisher; Howard T Thaler
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

4.  Peripheral arterial disease in the elderly: The Rotterdam Study.

Authors:  W T Meijer; A W Hoes; D Rutgers; M L Bots; A Hofman; D E Grobbee
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-02       Impact factor: 8.311

5.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

Authors:  J Niebauer; H D Volk; M Kemp; M Dominguez; R R Schumann; M Rauchhaus; P A Poole-Wilson; A J Coats; S D Anker
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

Review 6.  Oxidative stress during myocardial ischaemia and heart failure.

Authors:  R Ferrari; L Agnoletti; L Comini; G Gaia; T Bachetti; A Cargnoni; C Ceconi; S Curello; O Visioli
Journal:  Eur Heart J       Date:  1998-02       Impact factor: 29.983

7.  Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin.

Authors:  M A Hawk; K T Cesen; J C Siglin; G D Stoner; R J Ruch
Journal:  Cancer Lett       Date:  1996-12-03       Impact factor: 8.679

Review 8.  Medical treatment of peripheral arterial disease.

Authors:  Graeme J Hankey; Paul E Norman; John W Eikelboom
Journal:  JAMA       Date:  2006-02-01       Impact factor: 56.272

9.  Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.

Authors:  Sergio Mondillo; Piercarlo Ballo; Riccardo Barbati; Francesco Guerrini; Tiziana Ammaturo; Eustachio Agricola; Monica Pastore; Francesco Borrello; Mirko Belcastro; Andrea Picchi; Renato Nami
Journal:  Am J Med       Date:  2003-04-01       Impact factor: 4.965

10.  Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample.

Authors:  M Lindroos; M Kupari; J Heikkilä; R Tilvis
Journal:  J Am Coll Cardiol       Date:  1993-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.